Research programme: Alzheimer's disease vaccines - MAPP Biopharmaceutical
Latest Information Update: 09 Aug 2014
At a glance
- Originator Mapp Biopharmaceutical
- Class Monoclonal antibodies
- Mechanism of Action Amyloid beta-protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 09 Aug 2014 No development reported - Preclinical for Alzheimer's disease in USA (Intraperitoneal)
- 13 Nov 2010 Preclinical trials in Alzheimer's disease in USA (Intraperitoneal)